Objectives: To give an overview of the literature concerning the clinical practice of Botulinum toxin A (BTA) treatment to meet the needs and knowledge of urologists. Methods: A literature search was performed to BTA treatment, together with a survey among Dutch urologist. Results: The registration trials used strict inclusion and exclusion criteria, a standardized application technique and follow-up. The approval for BTA is based on these trials but differs from country to country. BTA was already used before these approvals, with different application techniques. Published manuscripts about application techniques (trigone sparing/suburothelial injections/intradetrusor injections) show different outcomes. In literature there is no positive or negative predictor found with a preoperatively urodynamic investigation. It is shown that retreatment does not cause inflammatory infiltration or fibrosis in the bladder wall. The survey showed that in 96% of the urology departments BTA is used. Urodynamic investigation is requested by 87% of urologists before the treatment. Although it is regarded as an easy-to-learn procedure 60% of urologists would like training in practical aspects. Conclusions: No firm data exist about the technique of application with consequently the most optimal results. BTA treatment is regarded as an easy-to-learn, but still there is a request for training in practical treatment aspects.

Keywords:
OnabotulinumtoxinA, Botulinum toxin, Neurogenic detrusor overactivity, Overactive bladder, Urinary incontinence
1.
Chapple C, et al: OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-256.
2.
Nitti VW, et al: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-2193.
3.
Cruz F, et al: Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-750.
4.
Ginsberg D, et al: Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-2139.
9.
Karsenty G, et al: Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract, 2014;68:731-742.
10.
Hermieu JF, et al: [Guidelines for practical usage of botulinum toxin type A (BoNTA) for refractory idiopathic overactive bladder management]. Prog Urol 2013;23:1457-1463.
11.
CBG: http://db.cbg-meb.nl/IB-teksten/h17379.pdf (retrieved August 4, 2014).
12.
Ravindra P, Jackson BL, Parkinson RJ: Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®)) or abobotulinumtoxinA (Dysport(®)) make a difference? BJU Int 2013;112:94-99.
13.
Stoehrer M, et al: Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 2009;83:379-385.
14.
Abdel-Meguid TA: Botulinum toxin-A injections into neurogenic overactive bladder - to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 2010;184:2423-2428.
15.
Karsenty G, et al: Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177:1011-1014.
16.
Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007;178:1359-1363.
17.
Kuo HC: Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011;30:1242-1248.
18.
Šámal V, Mečl J, Šrám J: Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int 2013;91:423-428.
19.
Mehnert U, et al: A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 2009;27:397-403.
20.
Coelho A, et al: Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 2012;61:1178-1184.
21.
Schmid DM, et al: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-185.
22.
Grosse J, et al: 647Is the outcome of multifocal botulinum A toxin BT.A in svere neurogenic detrusor overactivity NDO predictable - an urodynamic analysis. Eur Urol Suppl 2005;4:164.
23.
Rovner E, et al: OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2013;32:1109-1115.
24.
Rovner E, et al: Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556-562.
25.
Comperat E, et al: Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50:1058-1064.
26.
Apostolidis A, et al: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009;55:100-120.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.